Seroatlas · Human Serome Atlas

TRAV30

T cell receptor alpha variable 30

Also known as: TVA30_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: A0A087WSZ9
Gene: TRAV30
Ensembl: ENSG00000259092
Chromosome: 14
Canonical length: 112 aa
Protein class: Predicted intracellular proteins, T-cell receptor genes
Quaternary structure: Homodimer

OverviewNCBI Gene

T cell receptors recognize foreign antigens which have been processed as small peptides and bound to major histocompatibility complex (MHC) molecules at the surface of antigen presenting cells (APC). Each T cell receptor is a dimer consisting of one alpha and one beta chain or one delta and one gamma chain. In a single cell, the T cell receptor loci are rearranged and expressed in the order delta, gamma, beta, and alpha. If both delta and gamma rearrangements produce functional chains, the cell expresses delta and gamma. If not, the cell proceeds to rearrange the beta and alpha loci. This region represents the germline organization of the T cell receptor alpha and delta loci. Both the alpha and delta loci include V (variable), J (joining), and C (constant) segments and the delta locus also includes diversity (D) segments. The delta locus is situated within the alpha locus, between the alpha V and J segments. During T cell development, the delta chain is synthesized by a recombination event at the DNA level joining a D segment with a J segment; a V segment is then joined to the D-J gene. The alpha chain is synthesized by recombination joining a single V segment with a J segment. For both chains, the C segment is later joined by splicing at the RNA level. Recombination of many different V segments with several J segments provides a wide range of antigen recognition. Additional diversity is attained by junctional diversity, resulting from the random additional of nucleotides by terminal deoxynucleotidyltransferase. Five variable segments can be used in either alpha or delta chains and are described by TRAV/DV symbols. Several V and J segments of the alpha locus are known to be incapable of encoding a protein and are considered pseudogenes. [provided by RefSeq, Aug 2016]

Canonical amino-acid sequenceUniProt

112 residues, UniProt reviewed canonical sequence.

>A0A087WSZ9|TRAV30
     1  METLLKVLSG TLLWQLTWVR SQQPVQSPQA VILREGEDAV INCSSSKALY SVHWYRQKHG
    61  EAPVFLMILL KGGEQKGHDK ISASFNEKKQ QSSLYLTASQ LSYSGTYFCG TE

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against TRAV30 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 0
Highest tissue expression: 13 nTPM

Expression across tissuesHPA

Tissue

thymus: 13 nTPM
lymph node: 6 nTPM
tonsil: 3.4 nTPM
kidney: 2 nTPM
liver: 1.9 nTPM
fallopian tube: 1.6 nTPM

Single-cell type

epididymal efferent duct absorptive cells: 1.1 nCPM
fallopian tube ciliated cells: 0.5 nCPM
endometrial ciliated cells: 0.4 nCPM
t-cells: 0.3 nCPM
epididymal basal cells: 0.2 nCPM
enteric stem cells: 0.1 nCPM

Immune cell

T-reg: 43 nTPM
naive CD4 T-cell: 36 nTPM
memory CD4 T-cell: 24 nTPM
naive CD8 T-cell: 23 nTPM
memory CD8 T-cell: 21 nTPM
total PBMC: 12 nTPM

Brain region

midbrain: 0.8 nTPM
cerebellum: 0.3 nTPM
medulla oblongata: 0.3 nTPM
white matter: 0.3 nTPM
cerebral cortex: 0.2 nTPM
hippocampal formation: 0.2 nTPM

OntologyGO

Biological processes

Cellular components

T cell receptor complex

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads TRAV30 as an antibody target. Whether an autoantibody or antibody against TRAV30 could matter depends on whether native TRAV30 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

TRAV30 is annotated at the cell surface, where native TRAV30 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label TRAV30 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...